Free Access
Med Sci (Paris)
Volume 22, Number 1, Janvier 2006
Page(s) 7 - 9
Section Nouvelles
Published online 15 January 2006
  1. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346 : 561–4. [Google Scholar]
  2. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365 ; 61–5. [Google Scholar]
  3. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258 : 1946–9. [Google Scholar]
  4. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50 : 83–90. [Google Scholar]
  5. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol : a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215 : 89–97. [Google Scholar]
  6. McAllister SD, Glass M. CB(1) and CB(2) receptor-mediated signalling : a focus on endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 2002; 66 : 61–171. [Google Scholar]
  7. Howlett AC, Johnson MR, Melvin LS, Milne GM. Nonclassical cannabinoid analgetics inhibit adenylate cyclase : development of a cannabinoid receptor model. Mol Pharmacol 1988; 33 : 297–302. [Google Scholar]
  8. Bouaboula M, Poinot-Chazel C, Marchand J, et al. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem 1996; 237 : 704–11. [Google Scholar]
  9. Daaka Y, Zhu W, Friedman H, Klein TW. Induction of interleukin-2 receptor alpha gene by delta9-tetrahydrocannabinol is mediated by nuclear factor kappaB and CB1 cannabinoid receptor. DNA Cell Biol 1997; 16 : 301–9. [Google Scholar]
  10. Jeon YJ, Yang KH, Pulaski JT, Kaminski NE. Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor kappa B/Rel activation. Mol Pharmacol 1996; 50 : 334–41. [Google Scholar]
  11. Lutz B. Molecular biology of cannabinoid receptors. Prostaglandins Leukot Essent Fatty Acids 2002; 66 : 123–42. [Google Scholar]
  12. Klein TW, Newton C, Larsen K, et al. The cannabinoid system and immune modulation. J Leukoc Biol 2003; 74 : 486–96. [Google Scholar]
  13. Srivastava MD, Srivastava BI, Brouhard B. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 1998; 40 : 179–85. [Google Scholar]
  14. Yuan M, Kiertscher SM, Cheng Q, et al. Delta 9-tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol 2002; 133 : 124–31. [Google Scholar]
  15. Malfait AM, Gallily R, Sumariwalla PF, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 2000; 97 : 9561–6. [Google Scholar]
  16. Buckley NE, McCoy KL, Mezey E, et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 2000; 396 : 141–9. [Google Scholar]
  17. Steffens S, Veillard NR, Arnaud C, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005; 434 : 782–6. [Google Scholar]
  18. Rinaldi-Carmona M, Barth F, Millan J, et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 1998; 284 : 644–50. [Google Scholar]
  19. Mittleman MA, Lewis RA, Maclure M, et al. Triggering myocardial infarction by marijuana. Circulation 2001; 103 : 2805–9. [Google Scholar]
  20. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion : results of a randomised controlled trial. Pain 2004; 112 : 299–306. [Google Scholar]
  21. Wade DT, Robson P, House H, et al. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17 : 21–9. [Google Scholar]
  22. Burstein SH, Audette CA, Breuer A, et al. Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities. J Med Chem 1992; 35 : 3135–41. [Google Scholar]
  23. Burstein SH. Ajulemic acid (CT3) : a potent analog of the acid metabolites of THC. Curr Pharm Des 2000; 6 : 1339–45. [Google Scholar]
  24. Sumariwalla PF, Gallily R, Tchilibon S, et al. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum 2004; 50 : 985–98. [Google Scholar]
  25. Ibrahim MM, Porreca F, Lai J, et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA 2005; 102 : 3093–8. [Google Scholar]
  26. Ibrahim MM, Deng H, Zvonok A, et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain : pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 2003; 100 : 10529–33 [Google Scholar]
  27. Malan TP Jr, Ibrahim MM, Lai J, et al. CB2 cannabinoid receptor agonists : pain relief without psychoactive effects ? Curr Opin Pharmacol 2003; 3 : 62–7. [Google Scholar]
  28. Hanus L, Breuer A, Tchilibon S, et al. HU-308 : a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 1999; 96 : 14228–33. [Google Scholar]
  29. Jiang W, Zhang Y, Xiao L, et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 2006 (sous presse). [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.